Skip to main content
Screener/Healthcare/Biotechnology

HALO — Halozyme Therapeutics, Inc.

NASDAQ
$102.37+16.61 (+19.37%)
Mid CapHealthcareFastest GrowingHigh ROE
$61.23
$103.30
$90.00
$102.65
EPS (TTM)$2.49
P/E Ratio41.11
Dividend Yield—
Market Cap$9.87B
Volume6.50M
Prev Close$85.76
Revenue & Operating Income
Revenue
Operating Income
Net Income
Positive
Negative
Free Cash Flow
Positive
Negative
Gross Profit & Operating Expenses
Gross Profit
Operating Expenses
Earnings Per Share
Positive
Negative
Balance Sheet
Total Assets
Total Liabilities
Cash & Equivalents
Cash & Equivalents
Shares Outstanding
Shares Outstanding
Margins
Gross Margin
Operating Margin
Net Margin

Quarterly Results

QuarterRevenueNet IncomeEPSGross MarginNet Margin
Q4 '25$451.8M-$141.6M$-1.2077.4%-31.3%
Q3 '25$354.3M$175.2M$1.4384.4%49.5%
Q2 '25$325.7M$165.2M$1.3385.8%50.7%
Q1 '25$264.9M$118.1M$0.9381.7%44.6%
Q4 '24$298.0M$137.0M$1.0685.9%46.0%
Q3 '24$290.1M$137.0M$1.0583.0%47.2%
Q2 '24$231.4M$93.2M$0.7275.2%40.3%
Q1 '24$195.9M$76.8M$0.6076.5%39.2%
Get Your Daily Market Recap